摩根士丹利发表报告指将国药控股2025至2030年盈利预测下调1%至6%原因是医疗设备和药物分销部门的销售额预测被下调。

智通财经
15 Jul
摩根士丹利发表报告指将国药控股2025至2030年盈利预测下调1%至6%原因是医疗设备和药物分销部门的销售额预测被下调。该行对其目标价由23港元下调至22.5港元评级“增持”。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10